Healthcare Contract Research Outsourcing Market

Healthcare Contract Research Outsourcing Market Size (2023 to 2028)

The worldwide healthcare contract research outsourcing market was valued at USD 41.8 billion in 2023 and is anticipated to reach nearly USD 56.81 billion by 2028, with a CAGR of 6.29% from 2023 to 2028.

The rising number of mergers and acquisitions among biopharmaceutical and pharmaceutical industries is one of the key drivers boosting the market growth during the forecast period. For instance, in January 2021, Charles River Laboratories, a U.S.-based pharmaceutical company, acquired HemaCare, a global provider of biological blood products and services. Charles River Laboratories specializes in a variety of preclinical and clinical laboratory, gene therapy, and cell therapy services for the pharmaceutical, medical device, and biotechnology industries.

The increasing patent expiration is the second key driver fuelling the growth of the market during the projected period. The global market for contract research outsourcing in healthcare is anticipated to expand as more patents expire. For instance, the patents for two drugs, Atrovent HFA (ipratropium hfa) from Boehringer Ingelheim and Bydureon (exenatide) from AstraZeneca, both used to treat type 2 diabetes, expire in 2023; hence, this factor propels the market growth during the projected period. 

The emerging prevalence of chronic illnesses is the third factor favoring the market growth during the forecast period. The burden placed on various biopharmaceutical companies to carry out research and development operations rises along with the frequency of chronic illnesses. As a result, the market for international contract research outsourcing in healthcare is expanding quickly. In India, for instance, the prevalence of self-reported chronic disease was 21 per 100 elderly people in 2022, with 19% of the elderly suffering from chronic diseases in rural areas and 34% in urban areas, according to a report published in 2022 by PubMed, a free search engine of biological databases and medical reports. Hence, this factor also propels the market growth during the projected period. 

The other factors fuelling the market growth include the launches of new products, rising expenditure in R&D programs, the inclination for outsourced tasks due to cost and time limitations, and the expiration of the patent, which contributed to the expansion of the market during the projected period. 

The data privacy of the patient and security breaches are the major factors hampering the growth of the market during the projected period. The worldwide healthcare contract research outsourcing market's expansion may be hampered by the numerous patient data and information vulnerabilities that can result from a lack of direct supervision. For instance, on May 20, 2023, Capita plc., an outsourcing company and government healthcare contractor, disclosed that a cyber-attack in which hackers gained access to customer, supplier, and employee data resulted in losses of up to US$ 24 Mn. The lack of control over the quality of the product furthermore restricts the market growth. There is a chance that quality requirements cannot be met if medicine manufacturing is outsourced, which could damage the company's reputation. Variations in the regulatory guideline and approval process in different countries also delay in providing service, further hindering the market growth during the projected period. 

Impact of COVID-19 on the healthcare contract research outsourcing market:

The pandemic crisis has positively impacted the global healthcare contract research outsourcing market. The rising collaboration and partnership between biopharmaceutical companies to meet the shortage and demand of drugs. For instance, in July 2020, Piramal Critical Care (a Piramal Enterprises Limited subsidiary), a manufacturer of inhaled painkillers and hospital generics, announced an arrangement with a U.S.-based pharmaceutical outsourcing company, Medivant Healthcare, to dispense single-dose injectable drugs in approved states for COVID-19 patients who had a shortage in supply. The strict restrictions during the pandemic led to rising demand for virtual and decentralized clinical trials, and contract research outsourcing had to be adopted by offering more virtual monitoring, telemedicine services, and remote data collection solutions. The pandemic led to disruption in the global supply chain, impacting the availability of necessary equipment, drugs, and materials for clinical trials; this affected the ability of contract research outsourcing to conduct trials smoothly. 

REPORT COVERAGE:

This research report on the global healthcare contract research outsourcing market has been segmented and sub-segmented based on the following categories.

Healthcare Contract Research Outsourcing Market – By Services Type:

• Clinical Trials
  • Drug Discovery
  • Preclinical Phase I
  • Preclinical Phase II
  • Preclinical Phase III
  • Preclinical Phase IV
• Regulatory Services
• Medical Writing
• Clinical Data Management
• Others

Based on the services type, the clinical trials segment is predicted to hold the dominant position in the market during the projected period; the globally rising prevalence of chronic conditions contributed to the expansion of the market during the projected period. In the clinical trial segment, the drug discovery sub-segment is predicted to hold a notable share of the market due to increasing research and development activities. 

Clinical data management is another segment anticipated to hold a significant share of the market during the projected period. The demand for clinical data management services is driven by strict regulatory regulations and the need for data accuracy, accountability, and authenticity.

Healthcare Contract Research Outsourcing Market – By End-User:

• CROs
• Clinical Trial Laboratories
• AMCs

Based on the end-user, the CRO segment is predicted to hold a significant share of the market during the projected period. Rising research and development outsourced by pharmaceutical companies to reduce the expenses associated with the internal testing platform is ascribed to fuel the CROs healthcare contract research outsourcing market. 

The clinical trial laboratories segment is also anticipated to hold a significant share of the market during the forecast period. Complex clinical trials, such as those involving advanced therapeutics, personalized medicine, and rare illnesses, are being carried out by the pharmaceutical and biotechnology sectors. The demand for clinical trial laboratory services is fueled by the recognition that these trials frequently need complex and specialized laboratory testing and analysis.

Healthcare Contract Research Outsourcing Market – By Region:

• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East and Africa

North America region is expected to hold the dominant position in the market during the projected period. This is a result of the rising number of acquisitions taking place in this region. For instance, to expand the scope of its CRO services, on May 11, 2023, Genesis Biotechnology Group, a U.S.-based business that offers services to support preclinical drug development programs from discovery to candidate selection, acquired JSS Medical Research, a Canadian business that offers consulting services to pharmaceutical companies with a focus on medical writing and statistical analysis.

Europe region is also projected to hold a significant share of the market during the forecast period. This region has huge pharmaceutical and biotechnology firms; these companies conduct extensive clinical trials and research, boosting the demand for CRO services. European countries have well-established regulatory authorities and expertise in navigating these complex regulatory landscapes. Also, the growing focus on rare diseases and the rising demand for CRO services in this region are additional factors that propel the market growth in this region. 

APAC region is also expected to grow at a significant CAGR during the projected period. The pharmaceutical and biotechnology industries have experienced enormous growth in APAC nations, particularly China and India. These nations are now significant centers for pharmaceutical research and development, making them desirable locations for clinical trials and CRO services. Access to a large and varied patient population is provided by APAC nations, which is essential for conducting clinical research with a range of genetic and demographic characteristics.

Latin America and Middle East and Africa are also expected to hold a notable share of the market during the projected period. 

KEY MARKET PLAYERS:

The prominent key players in the global healthcare contract research outsourcing market are Syneos Health PAREXEL International ICON plc, PRA Health Sciences, Inc. Charles River Laboratory Corporation of America Holdings (Covance), IQVIA.

RECENT DEVELOPMENT IN THE MARKET:

• In November 2021, Envigo, a privately held contract research organization and laboratory animal source based in London, has been acquired by Inotiv, a company that offers non-clinical and analytical drug discovery and development services, research models, and related products and services, in order to aid in the discovery and preclinical stages of the development of new drugs and medical devices.
• In April 2021, The acquisition of Q2 Solutions from Quest Diagnostics, a clinical laboratory with headquarters in the United States, was announced by IQVIA Inc., a global provider of advanced analytics, technological solutions, and clinical research services to the life sciences sector.